Holen Sie sich die Stockscreener-App
59.60
2.56%
1.49
Handel nachbörslich:
59.60
Schlusskurs vom Vortag:
$58.11
Offen:
$58.22
24-Stunden-Volumen:
1.47M
Relative Volume:
1.87
Marktkapitalisierung:
$3.71B
Einnahmen:
$45.48M
Nettoeinkommen (Verlust:
$169.95M
KGV:
22.75
EPS:
2.62
Netto-Cashflow:
$230.85M
1W Leistung:
+2.51%
1M Leistung:
+10.72%
6M Leistung:
+54.16%
1J Leistung:
+42.58%
1-Tages-Spanne:
$57.45
$60.71
1-Wochen-Bereich:
$57.45
$60.71
52-Wochen-Spanne:
$33.31
$61.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
59.60 | 3.66B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Transcript : Protagonist Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 09 - MarketScreener
Real time social sentiment graph for Protagonist Therapeutics Inc.Earnings Overview Summary & Community Consensus Picks - Newser
Comparing Protagonist Therapeutics Inc. in custom built stock radars2025 Price Momentum & Community Driven Trade Alerts - Newser
What’s the recovery path for long term holders of Protagonist Therapeutics Inc.2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
What to do if you’re stuck in Protagonist Therapeutics Inc.2025 Retail Activity & Safe Capital Growth Tips - Newser
What momentum shifts mean for Protagonist Therapeutics Inc.Stop Loss & Daily Stock Trend Reports - Newser
Protagonist Therapeutics Inc. stock trendline breakdownWeekly Volume Report & Step-by-Step Swing Trade Plans - Newser
How to build a custom watchlist for Protagonist Therapeutics Inc.July 2025 Momentum & Low Risk High Reward Trade Ideas - Newser
Live market analysis of Protagonist Therapeutics Inc.July 2025 Volume & Smart Investment Allocation Insights - Newser
Applying Wyckoff theory to Protagonist Therapeutics Inc. stock2025 Price Momentum & Scalable Portfolio Growth Methods - Newser
Can technical indicators confirm Protagonist Therapeutics Inc.’s reversal2025 Macro Impact & Fast Entry Momentum Alerts - Newser
What MACD signals say about Protagonist Therapeutics Inc.Weekly Gains Summary & Risk Managed Trade Strategies - Newser
Has Protagonist Therapeutics Inc. formed a bullish divergencePortfolio Return Summary & Precise Buy Zone Tips - Newser
Buyback Watch: Is Protagonist Therapeutics Inc. being accumulated by smart money2025 Historical Comparison & Fast Entry and Exit Trade Plans - khodrobank.com
Combining machine learning predictions for Protagonist Therapeutics Inc.2025 Earnings Impact & Fast Moving Stock Watchlists - Newser
Protagonist Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & High Yield Equity Trading Tips - Newser
Institutional scanner results for Protagonist Therapeutics Inc.July 2025 Volume & Expert Approved Momentum Ideas - Newser
Will Protagonist Therapeutics Inc. benefit from rate cutsJuly 2025 Pullbacks & AI Powered Trade Plan Recommendations - khodrobank.com
Is Protagonist Therapeutics Inc. a cyclical or defensive stockJuly 2025 Action & AI Optimized Trade Strategies - khodrobank.com
Can Protagonist Therapeutics Inc. expand into new marketsJuly 2025 Setups & Momentum Based Trading Ideas - khodrobank.com
Custom watchlist performance reports with Protagonist Therapeutics Inc.2025 Investor Takeaways & Consistent Growth Stock Picks - Newser
Can Protagonist Therapeutics Inc. continue delivering strong returnsTrade Signal Summary & Weekly Stock Performance Updates - khodrobank.com
Analyzing drawdowns of Protagonist Therapeutics Inc. with statistical toolsEarnings Beat & Technical Buy Zone Confirmation - Newser
Hedge Fund Bets: Will Protagonist Therapeutics Inc. benefit from geopolitical trendsJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - khodrobank.com
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - Lancaster Eagle-Gazette
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Greenville Online
Does Protagonist Therapeutics Inc. stock pay reliable dividendsJuly 2025 Chart Watch & Free High Return Stock Watch Alerts - Newser
Has Allogene Therapeutics Inc. found a price floorEarnings Risk Report & Fast Gain Swing Alerts - Newser
What does recent volatility data suggest for Protagonist Therapeutics Inc.Market Volume Report & Daily Entry Point Trade Alerts - Newser
How to use Fibonacci retracement on Protagonist Therapeutics Inc.Quarterly Investment Review & Reliable Volume Spike Alerts - Newser
Published on: 2025-08-31 13:08:30 - Newser
Published on: 2025-08-31 13:03:05 - Newser
Published on: 2025-09-01 15:39:15 - Newser
Strategies to average down on Protagonist Therapeutics Inc.Market Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Volume Surge May Signal Institutional Interest in Protagonist Therapeutics Inc.Trade Ideas & Fast Momentum Entry Tips - beatles.ru
Is Protagonist Therapeutics Inc. stock bottoming outMarket Activity Summary & AI Optimized Trading Strategy Guides - Newser
Published on: 2025-08-30 22:08:34 - Newser
Real time scanner hits for Protagonist Therapeutics Inc. explainedQuarterly Market Summary & Safe Capital Allocation Plans - Newser
Visualizing Protagonist Therapeutics Inc. stock with heatmapsVolume Spike & Fast Exit Strategy with Risk Control - Newser
Published on: 2025-08-30 05:05:17 - Newser
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):